NerPharMa and ICROM sealed Partnership Agreement
NMS Group
May 6, 2021

Nerviano, 6 May 2021 NerPharMa, a veteran CDMO with a specialization in oncology small molecule drug manufacture and a member of NMS Group, has announced today a Partnership Agreement with ICROM srl, aiming for collaboration on commercial production of High Potent drugs and ADC-Payload. This agreement outlines the sharing of technologies, know-how, facilities and workforce of the two companies to offer API development and formulated drug production services to third-party companies in increasingly strategic sectors of oncology and neurology.

“The structural growth of the API division is a key component in NerPharMa’s strategic plan. In order to reach the highest potential of our facilities, we see the partnership with ICROM as an essential step to accelerate the process to offer our customers concrete and qualitatively high-tech solutions in a very short time”, said Angelo Colombo CEO of NerPharMa.”

“We are extremely excited about this partnership with a leading enterprise that has been operating in the sector with proven successes for many years” said Pierfrancesco Morosini, CEO of ICROM, “I am absolutely convinced that the synergy of the capabilities and potentials of the two companies will bring us mutually beneficial outcome, in this fierce global competition context.”

About NerPharMa
NerPharMa owns a wide and cutting-edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products intended for the world market as well as the research and development of innovative formulation and delivery systems. In Nerpharma there are two divisions:
NerPharMa DS (drug substance) and NerPharMa DP (drug product)The two divisions operate in accordance with Current Good Manufacturing Practices (cGMP) and are authorized by the most relevant authorities: Italian Drug Agency (AIFA), U.S. Food and Drug Administration (FDA), ANVISA Brazil, China FDA, PMDA Japan and Russia for the production of both pharmaceutical active ingredients and finished products.


ICROM srl is an Italian CDMO dedicated to the development and the GMP manufacturing of Active Ingredients and Intermediates for pharmaceutical use on a small, medium and large scale.
ICROM holds segregated GMP units for the development and manufacture of diagnostic dyes as well as for high-potent APIs mainly for oncological application, supporting clinical phases (both in USA and EU) as well as commercial productions of Specialty Drugs.
All Icrom’s facilities are regularly inspected and approved by the main Regulatory Agencies (EMA, US-FDA, Japanese PMDA) so to efficiently support projects targeting a global presence on the worldwide pharmaceutical markets.
ICROM can follow the drug development efforts of its clients from the preclinical stages through all the clinical phases and up to the drug’s commercial manufacturing by the design and the development of an efficient and scalable manufacturing process in compliance with the most recent regulatory requirements.


About NMS Group

NMS Group is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group’s innovation, securing global recognition of NMS in personalized therapy. Recently Entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group. 

The NMS Group has three subsidiaries. NMS srl is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization. 


Welcome and Check out our new motion picture!